Online Program

Drug review and approval in US and Europe, adverse effects, hospital use, prior approval

Tuesday, November 5, 2013: 12:30 p.m. - 2:00 p.m.
This session will review some emerging issues at intersection of public health and pharmacy. The issues range from the concerns of medications in the environment to the diversion of drugs of abuse. Attendees will learn how other public health practitioners and other health professionals are studying these issues and how their learned lessons can be applied to other settings
Session Objectives: Describe two issues related to the use of drugs and their impact of the costs associated with hospital utilization Discuss the concern of medications in the environment and how public health officials and the pharmaceutical industry need to change in response Compare the drug approval processes between the US and European Union and discuss a concern related to the drug approval process in the US
Andrew Peterson, PharmD, PhD
Andrew Peterson, PharmD, PhD

Association of prescribed opioid analgesics, benzodiazepines, and antidepressants with duration of hospitalization: A national cohort study   
Barbara Turner, MD, MSED, MACP, Yuanyuan Liang, PhD, Christopher Louden, MS, Benjamin Ehler, MS and KoKo Aung, MD, MPH
A comparison of new drugs approved by the EMA and the FDA in 1999-2011   
Saad Alqahtani, B.Sc.Pharm, Nasser Alshehri, PharmD, Ebtissam Badawoud, B.Sc.Pharm, Enrique Seoane-Vazquez, PhD and Rosa Rodriguez-Monguio, PhD, MS

See individual abstracts for presenting author's disclosure statement and author's information.

Organized by: Medical Care
Endorsed by: Injury Control and Emergency Health Services

See more of: Medical Care